PDCD1 and neoplasm: To evade the antitumor immunity, cancer cells upregulate PD-L1, which interacts with its receptor (PD-1) on T lymphocytes, causing cytotoxic T cell dysfunction; moreover, other tumor-infiltrating immune or stromal cells may favor immunosuppression [158].